Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1157/13119725 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Orlistat-induced oxalate nephropathy: an under-recognised cause of chronic kidney disease.
BMJ Case Rep
November 2017
Department of Histopathology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK.
Two patients developed kidney failure due to oxalate deposition in the kidney while taking orlistat. Cessation of orlistat was followed by partial recovery of kidney function. The mechanism by which orlistat causes hyperoxaluria and the management of orlistat-induced oxalate nephropathy is reviewed.
View Article and Find Full Text PDFImpact of Dietary Lipids on Colonic Function and Microbiota: An Experimental Approach Involving Orlistat-Induced Fat Malabsorption in Human Volunteers.
Clin Transl Gastroenterol
April 2016
Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile.
Objectives: High-fat diets alter gut microbiota and barrier function, inducing metabolic endotoxemia and low-grade inflammation. Whether these effects are due to the high dietary lipid content or to the concomitant decrease of carbohydrate intake is unclear. The aim of this study was to determine whether higher amounts of dietary fat reaching the colon (through orlistat administration) affect the colonic ecosystem in healthy volunteers and the effect of the prebiotic oligofructose (OF) in this model.
View Article and Find Full Text PDFOrlistat-induced fulminant hepatic failure.
Clin Obes
December 2014
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH, USA.
Orlistat was approved by the Food and Drug Administration in 1998 and has been shown to be superior to placebo in achieving weight loss. It is generally well tolerated. However, severe liver injury has been reported.
View Article and Find Full Text PDFAcute pancreatitis following orlistat therapy: report of two cases.
JOP
January 2010
Department of General Surgery, Hairmyres Hospital, East Kilbride, G75 8RG, United Kingdom.
Context: Orlistat is a pancreatic lipase inhibitor licensed for the treatment of obesity. As obesity rates increase and non-prescription dispensing of orlistat increases, an awareness of its adverse effects is of crucial importance as complications arise more frequently from increased use. Orlistat induced pancreatitis has been described only once previously, but without a diagnostic increase in serum amylase.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!